Christina Mattina

Biomarker testing is critical for determining optimal therapy early in the non–small lung cancer (NSCLC) treatment process, but research shows uneven insurance coverage of these tests and inconsistent uptake in cancer centers.

Lung cancer is tied to tobacco smoking in the public consciousness, but a significant proportion of cases are driven by factors like indoor and outdoor air pollution or ancestral genetic variants.

Data presented in the second Presidential Symposium at the 2024 World Conference on Lung Cancer showed encouraging responses to novel agents among patients with HER2-mutated non–small cell lung cancer (NSCLC).

Lung cancer screening experts from around the globe delivered strategies and best practices for improving access to screening and facilitating earlier detection at the 2024 World Conference on Lung Cancer.

The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of pembrolizumab, but results presented at the 2024 World Conference on Lung Cancer could shake up that status quo.

The 2024 World Conference on Lung Cancer (WCLC), meeting in San Diego, California, from September 7 to 10, 2024, will feature practice-changing data and discussion in the lung cancer space.

Discussions of social determinants of health might focus on the obvious ones—like income or education—while overlooking some other social determinants that impact health in complex ways.

A recent study estimates the prevalence of primary care and emergency department visits by young children to treat respiratory syncytial virus (RSV), finding that the rates vary widely by country.

Legal and policy experts on a KFF webinar explained how the Supreme Court’s recent decision to overturn the Chevron precedent will impact legislators, agencies, and courts as they interpret and enforce policies in the health care realm.

Enthusiasm abounded at the recent European Hematology Association 2024 Congress about whether European regulators will begin to consider minimal residual disease (MRD) as an end point.

The late-breaking oral session at the European Hematology Association (EHA) 2024 Congress featured new data from abstracts submitted after the deadline, including both interventional and foundational science.

At a session of the European Hematology Association 2024 Congress, presenters shared updates from trials of treatment strategies for newly diagnosed multiple myeloma (MM).

At a friendly debate held at the European Hematology Association 2024 Congress, hemophilia experts argued for and against wider access to gene therapy for patients living with the condition.

Abstracts presented at the 2024 European Hematology Association Congress deliver results on regimens involving venetoclax for chronic lymphocytic leukemia (CLL).

Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.

At a YoungEHA session at the 2024 European Hematology Association (EHA) Congress, speakers discussed the prevalence of waste in laboratories, research, and clinical practice, as well as ways attendees can effect change for a more sustainable future.

A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary.

The 2024 European Hematology Association (EHA) Congress, convening virtually and in Madrid, Spain, from June 13-16, 2024, will feature practice-changing findings in hematology and oncology, as well as ample networking opportunities and conversations about the future of the field.

At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.

A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

By prioritizing well-being, both the public and private sectors can come together in partnerships to address social needs and social determinants of health.

As CMS’ suite of value-based and accountable care models evolves, leaders from across the agency detailed how they are working together to streamline quality reporting and encourage the move to a population health mindset while addressing providers’ concerns.

Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma secretase inhibitor to treat progressing desmoid tumors.

A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.

After years of efforts to reduce low-value care, panelists at the 2024 Value-Based Insurance Design Summit proposed a new strategy: drawing a line in the sand that payers will not be on the hook for these services.

During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.

Study findings show that scores on the Psoriasis Area and Severity Index and the Dermatology Quality of Life Index are correlated in patients with psoriasis across several continents, but factors affecting each of these scores are different across countries.

The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.

A provision in the Inflation Reduction Act will implement a $2000 out-of-pocket cap on Medicare beneficiaries’ prescription drug spending, which could save money for more than 1 million enrollees when it takes effect next year.